Literature DB >> 16490815

Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents.

Pramod K Kuchulakanti1, William W Chu, Rebecca Torguson, Patrick Ohlmann, Seung-Woon Rha, Leonardo C Clavijo, Sang-Wook Kim, Ahn Bui, Natalie Gevorkian, Zhenyi Xue, Kimberly Smith, Jana Fournadjieva, William O Suddath, Lowell F Satler, Augusto D Pichard, Kenneth M Kent, Ron Waksman.   

Abstract

BACKGROUND: Stent thrombosis (ST) is a serious complication of drug-eluting stent (DES) implantation regardless of the timing (acute, subacute, or late). The correlates of ST with DES are not yet completely elucidated. METHODS AND
RESULTS: From a total cohort of 2974 consecutive patients treated with DES since April 2003, we identified 38 patients who presented with angiographic evidence of ST (1.27%). The ST occurred acutely in 5 patients, subacutely (< or =30 days) in 25 patients, and late (>30 days) in 8 patients. The clinical, angiographic, and procedural variables of these patients were compared with the remaining 2936 consecutive patients who underwent DES implantation and did not experience ST during a follow-up of 12 months. Logistic regression analysis was conducted to determine the correlates of ST. Compared with patients without ST, patients with ST had a higher frequency of diabetes, acute postprocedural renal failure, and chronic renal failure. There were more bifurcation lesions, type C lesions, and a trend for smaller-diameter stents. Discontinuation of clopidogrel was higher in these patients (36.8% versus 10.7%; P<0.0001). The mean duration to ST from the stent implantation was 8.9+/-8.5 days in subacute and 152.7+/-100.4 days in late thrombosis cases. Mortality was significantly higher in patients with ST compared with those without ST at 6 months (31% versus 3%; P<0.001). Multivariate analysis detected cessation of clopidogrel therapy, renal failure, bifurcation lesions, and in-stent restenosis as significant correlates of ST (P<0.05).
CONCLUSIONS: ST continues to be a serious complication of contemporary DES use. Careful management is warranted in patients with renal failure and in those undergoing treatment for in-stent restenosis and bifurcations. Special focus on clopidogrel compliance may minimize the incidence of ST after DES implantation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16490815     DOI: 10.1161/CIRCULATIONAHA.105.600155

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  94 in total

1.  Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention.

Authors:  Patrik Htun; Suzanne Fateh-Moghadam; Christian Bischofs; Winston Banya; Karin Müller; Boris Bigalke; Konstantinos Stellos; Andreas E May; Marcus Flather; Meinrad Gawaz; Tobias Geisler
Journal:  J Am Soc Nephrol       Date:  2011-01-27       Impact factor: 10.121

2.  One-year clinical follow-up of a registry evaluating a percutaneous revascularisation strategy combining a pre-specified simple selection process with the use of a new thin-strut bare cobalt-chromium stent.

Authors:  P R Stella; G Pavlakis; P Agostoni; H M Nathoe; S Hoseyni Guyomi; B J Hamer; T X Wildbergh; P A Doevendans; E Van Belle
Journal:  Neth Heart J       Date:  2010-10       Impact factor: 2.380

Review 3.  Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications.

Authors:  Paul Galvin; Damien Thompson; Katie B Ryan; Anna McCarthy; Anne C Moore; Conor S Burke; Maya Dyson; Brian D Maccraith; Yurii K Gun'ko; Michelle T Byrne; Yuri Volkov; Chris Keely; Enda Keehan; Michael Howe; Conor Duffy; Ronan MacLoughlin
Journal:  Cell Mol Life Sci       Date:  2011-10-21       Impact factor: 9.261

Review 4.  Late stent thrombosis: the last remaining obstacle in coronary interventional therapy.

Authors:  Piera Capranzano; George Dangas
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

Review 5.  Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques.

Authors:  Shann S Yu; Ryan A Ortega; Brendan W Reagan; John A McPherson; Hak-Joon Sung; Todd D Giorgio
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-08-10

6.  Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practice.

Authors:  Jason C Kovacic; Paul Lee; Rucha Karajgikar; Usman Baber; Birju Narechania; Javed Suleman; Pedro R Moreno; Samin K Sharma; Annapoorna S Kini
Journal:  J Interv Cardiol       Date:  2012-06-22       Impact factor: 2.279

7.  The Canadian Association of Interventional Cardiology and the Canadian Cardiovascular Society joint statement on drug-eluting stents.

Authors:  Machael P Love; Erick Schampaert; Eric A Cohen; John G Webb; Todd J Anderson; Marino Labinaz; Jean-François Tanguay; Vladimír Dzavík
Journal:  Can J Cardiol       Date:  2007-02       Impact factor: 5.223

8.  Attenuated herpes simplex virus 1 blocks arterial apoptosis and intimal hyperplasia induced by balloon angioplasty and reduced blood flow.

Authors:  Christopher L Skelly; Amito Chandiwal; James E Vosicky; Ralph R Weichselbaum; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-12       Impact factor: 11.205

9.  Vascular pathology as a result of drug-eluting stents.

Authors:  Martin R Bennett
Journal:  Heart       Date:  2007-08       Impact factor: 5.994

10.  Stent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapy.

Authors:  P A Gurbel; D E Kandzari
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.